ATE231002T1 - Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus - Google Patents

Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus

Info

Publication number
ATE231002T1
ATE231002T1 AT93921646T AT93921646T ATE231002T1 AT E231002 T1 ATE231002 T1 AT E231002T1 AT 93921646 T AT93921646 T AT 93921646T AT 93921646 T AT93921646 T AT 93921646T AT E231002 T1 ATE231002 T1 AT E231002T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
pct
virus
synzytial
antibodies against
Prior art date
Application number
AT93921646T
Other languages
English (en)
Inventor
Dennis R Burton
Carlos F Barbas Iii
Robert M Chanock
Brian R Murphy
James E Crowe Jr
Original Assignee
Scripps Research Inst
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst, Us Gov Health & Human Serv filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE231002T1 publication Critical patent/ATE231002T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1006—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against or targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C07K16/11—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT93921646T 1992-09-16 1993-09-16 Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus ATE231002T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94551592A 1992-09-16 1992-09-16
PCT/US1993/008786 WO1994006448A1 (en) 1992-09-16 1993-09-16 Human neutralizing monoclonal antibodies to respiratory syncytial virus

Publications (1)

Publication Number Publication Date
ATE231002T1 true ATE231002T1 (de) 2003-02-15

Family

ID=25483204

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921646T ATE231002T1 (de) 1992-09-16 1993-09-16 Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus

Country Status (12)

Country Link
US (1) US5762905A (de)
EP (1) EP0671927B1 (de)
JP (1) JP3976333B2 (de)
AT (1) ATE231002T1 (de)
AU (1) AU686113B2 (de)
CA (1) CA2144043C (de)
DE (1) DE69332643T2 (de)
DK (1) DK0671927T3 (de)
ES (1) ES2191016T3 (de)
FI (2) FI108991B (de)
NO (1) NO323768B1 (de)
WO (1) WO1994006448A1 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
ATE194291T1 (de) * 1995-09-18 2000-07-15 Intracel Corp Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
JP2001510329A (ja) * 1996-11-01 2001-07-31 スミスクライン・ビーチャム・コーポレイション ヒトモノクローナル抗体
ITRM960808A1 (it) * 1996-11-26 1998-05-26 Rossolini Gianmaria Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia
FR2758331B1 (fr) * 1997-01-14 1999-03-05 Univ Bourgogne Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
CO5280147A1 (es) * 1999-05-18 2003-05-30 Smithkline Beecham Corp Anticuerpo humano monoclonal
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2001240020B9 (en) 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
WO2001055217A1 (en) 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
US20050175986A1 (en) * 2000-05-09 2005-08-11 Smit Kline Beecham Corporation Human monoclonal antibody
DE60135147D1 (de) * 2000-10-17 2008-09-11 Besst Test Aps Nen biologischen zelle in einer körperflüssigkeitsprobe
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2002365925A1 (en) * 2001-11-02 2003-09-02 Centocor Rsv proteins, antibodies, compositions, methods and uses
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US6919077B2 (en) * 2002-09-27 2005-07-19 Aids Research, Llc LFA-1 alpha subunit antibodies and methods of use
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
CA2580921C (en) 2004-09-21 2016-04-12 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
JP2008518936A (ja) * 2004-10-29 2008-06-05 メディミューン，インコーポレーテッド Ｒｓｖ感染症および関連状態を予防および治療する方法
AU2007222798A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
ES2553553T3 (es) 2006-10-02 2015-12-10 E. R. Squibb & Sons, L.L.C. Anticuerpos humanos que se unen a CXCR4 y usos de los mismos
WO2008070569A2 (en) 2006-12-01 2008-06-12 Medarex, Inc. Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP2097534A4 (de) 2006-12-14 2010-05-12 Medarex Inc Cd70-bindende antikörper und ihre verwendungen
AU2008224259A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US20110033389A1 (en) * 2009-04-29 2011-02-10 Zhifeng Chen Modified antibodies for passive immunotherapy
IN2012DN01328A (de) 2009-08-13 2015-06-05 Crucell Holland Bv
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
JP5744196B2 (ja) 2010-07-09 2015-07-08 クルセル ホランド ベー ヴェー 抗ヒト呼吸器多核体ウイルス（ｒｓｖ）抗体および使用の方法
IL210093A0 (en) 2010-12-19 2011-06-30 David Helman Membrane bound reporter molecules and their use in cell sorting
CL2011003002A1 (es) 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
BR112019008063A2 (pt) 2016-10-21 2019-07-02 Adimab, Llc anticorpos contra o vírus sincicial anti-respiratório e métodos de sua geração e uso
WO2018075954A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
EP3529270A2 (de) 2016-10-21 2019-08-28 Adimab, LLC Antikörper gegen das respiratorische synzytial-virus und verfahren zu deren erzeugung und verwendung
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
CN112135626B (zh) 2018-07-25 2023-05-23 信达生物制药(苏州)有限公司 抗tigit抗体及其用途
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
BR112022017174A2 (pt) 2020-02-27 2022-10-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
EP4151654A4 (de) 2020-05-12 2024-11-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. St2-antigenbindendes protein
TW202330617A (zh) 2021-11-25 2023-08-01 大陸商正大天晴藥業集團股份有限公司 抗Siglec-15抗體及其應用
EP4495138A1 (de) 2022-03-18 2025-01-22 Beijing Mabworks Biotech Co., Ltd B7-h3-bindender antikörper und verwendung davon
CN116063468A (zh) * 2022-08-30 2023-05-05 武汉班科生物技术有限公司 中和呼吸道合胞病毒的c-型单域抗体及应用
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
WO1991016074A1 (en) * 1990-04-19 1991-10-31 Medimmune, Inc. Administration of monoclonal antibodies against respiratory viruses
EP0539522B1 (de) * 1990-07-19 1998-12-30 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Verbesserte immunotherapeutische methode zur verhinderung oder behandlung viraler krankheiten der atemwege
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man

Also Published As

Publication number Publication date
US5762905A (en) 1998-06-09
EP0671927A1 (de) 1995-09-20
FI951164L (fi) 1995-05-12
AU4927193A (en) 1994-04-12
CA2144043A1 (en) 1994-03-31
JPH08505520A (ja) 1996-06-18
DE69332643D1 (de) 2003-02-20
NO950881L (no) 1995-05-15
FI20020184L (fi) 2002-01-31
DK0671927T3 (da) 2003-04-22
WO1994006448A1 (en) 1994-03-31
DE69332643T2 (de) 2003-11-27
FI108991B (fi) 2002-05-15
EP0671927A4 (de) 1997-05-21
JP3976333B2 (ja) 2007-09-19
ES2191016T3 (es) 2003-09-01
AU686113B2 (en) 1998-02-05
FI111553B (fi) 2003-08-15
CA2144043C (en) 2005-01-18
FI951164A0 (fi) 1995-03-13
EP0671927B1 (de) 2003-01-15
NO323768B1 (no) 2007-07-02
NO950881D0 (no) 1995-03-07

Similar Documents

Publication Publication Date Title
ATE231002T1 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
ATE194291T1 (de) Neutralisierende monoklonale antikörper gegen respiratorischen synzytialvirus
EP0675904A4 (de) Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch.
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
DE69426077D1 (de) Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
NO970221L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
IN2012DN00313A (de)
DK0807125T3 (da) Monoklonale antistoffer mod CD6 til behandling og diagnosticering af psoriasis
DE3750389D1 (de) Antikörper gegen menschlichen progesteronrezeptor sowie diagnosematerial und -verfahren.
FI972703A0 (fi) Rekombinantti IL-5-antagonisteja, jotka ovat käyttökelpoisia hoidettaessa IL-5:een liittyviä sairauksia
EA199900342A1 (ru) Способ создания активного иммунитета вакцинным конъюгатом
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
DE3587681D1 (de) Vakzine und Serum für Endotoxin assoziierte Krankheit und Verfahren zur Herstellung derselben sowie Verfahren zur Immunisierung und Behandlung solcher Krankheiten, enttoxifierte Endotoxine und bakterielle Mutante.
FR2725990B1 (fr) Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
ATE179331T1 (de) Das durch den monoklonalen menschlichen antikörper 81av78 erkannte antigen ctaa 81av78
AU6176596A (en) Compositions exhibiting adp-ribosyltransferase activity and methods for the preparation and use thereof
ATE144286T1 (de) Monoklonale antikörper gegen den plasmin- antiplasmin komplex, verfahren zu ihrer herstellung sowie ihre verwendung
DK0809653T3 (da) Helicobacter pylori-antigen
EP0854727A4 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung
GB9715177D0 (en) Medicament
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
NO980721L (no) Vaksiner
ES2088820A1 (es) Anticuerpos monoclonales antineumolisina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0671927

Country of ref document: EP

REN Ceased due to non-payment of the annual fee